These biomarkers function as critical indicators of inflammatory signaling, bridging the gap between innate and adaptive immune responses. By measuring these proteins in EDTA plasma, medical teams can monitor patients with higher precision, identifying potential rejection risks before clinical symptoms escalate. The company is positioning these tests as a vital addition to its existing immunology portfolio, specifically targeting the needs of solid organ and hematopoietic cell transplant recipients.
In section Releases
Eurofins Viracor Adds Cytokine Assays to Expand Transplant Monitoring
Clinicians managing transplant patients now have access to three new plasma-based biomarkers—CXCL9, CXCL10, and IL-18—designed to track T cell-mediated immune activation. Lenexa-based Eurofins Viracor launched the assays to offer a minimally invasive method for detecting early signs of allograft injury and chronic graft dysfunction in immunocompromised individuals.
Efficiency remains a primary focus for the rollout, with the laboratory committing to a 24-hour turnaround time for samples received by 11:00 a.m. CST. The assays are available for individual order or can be integrated into custom cytokine panels, allowing researchers and hospitals to tailor monitoring protocols to specific patient requirements. Those interested in clinical applications or testing specifications can reach the laboratory's support team at (800) 305-5198.
Comments (0)
No comments yet. Be the first!